Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOTRIN vs SPRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Primary dysmenorrhea,Fever reduction
Short-term management of moderate to moderate-severe acute pain (FDA-approved indication)
Ibuprofen (Motrin) 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day for acute pain, and 2400 mg/day for chronic use.
Intranasal: 31.5 mg (1 spray) in one nostril, may repeat after 30 minutes; maximum 63 mg (2 sprays) per dose. Subsequent doses every 6-8 hours as needed; maximum 126 mg (4 sprays) per day.
Terminal elimination half-life approximately 2-4 hours in adults with normal renal function; prolonged in elderly and patients with renal impairment (up to 6-8 hours). No significant accumulation occurs with regular dosing.
Terminal elimination half-life is 5-6 hours in adults with normal renal function; may be prolonged to 13-14 hours in elderly patients and 15-20 hours in patients with renal impairment.
Hepatic via CYP2C9 and glucuronidation; minor via CYP2C8.
Primarily hepatic via conjugation (glucuronidation) and oxidation (CYP2C9 minor). Metabolites are inactive.
Renal excretion of conjugated metabolites (approximately 70-80% as glucuronide and sulfate conjugates); less than 10% excreted unchanged. Biliary/fecal elimination accounts for about 10-20%.
Renal excretion of unchanged drug and metabolites; after intravenous administration, approximately 92% of the dose is recovered in urine (50% as unchanged ketorolac, 40% as glucuronide conjugates) and 6% in feces.
Highly protein-bound (approximately 99%) primarily to albumin.
99% bound to plasma proteins, primarily albumin (saturable at high concentrations).
Approximately 0.1-0.2 L/kg (range 0.1-0.2 L/kg); indicative of limited tissue distribution due to high protein binding. Larger Vd in neonates (0.3-0.4 L/kg).
0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid.
Oral immediate-release: 80-100%; oral extended-release: approximately 85-90% relative to immediate-release; intravenous: 100%; topical (e.g., gel): 3-8% systemic absorption.
Intranasal: approximately 75-80% relative to intravenous administration.
GFR 30-59 m L/min: use minimum effective dose, monitor renal function; GFR <30 m L/min: avoid use; dialysis: not removed by hemodialysis, avoid use.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-60 m L/min), reduce total daily dose by 50% and monitor for renal toxicity.
Child-Pugh Class A: no adjustment; Class B: use with caution, reduce dose by 50%; Class C: avoid use.
Contraindicated in Child-Pugh Class C cirrhosis. For mild to moderate hepatic impairment (Child-Pugh A or B), reduce total daily dose by 50% and monitor for signs of bleeding or hepatic toxicity.
Children 6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; maximum 40 mg/kg/day, not to exceed adult maximum; for fever >39°C, 10 mg/kg/dose; available as oral suspension (100 mg/5 m L).
Not recommended for use in pediatric patients (safety and efficacy not established).
Initiate at the lowest effective dose (e.g., 200-400 mg every 6-8 hours), maximum 3200 mg/day; monitor for GI bleeding and renal impairment; avoid prolonged use due to increased cardiovascular and GI risks.
Elderly patients may have increased risk of GI bleeding and renal toxicity. Use lowest effective dose and shortest duration; monitor renal function and adjust dose based on estimated glomerular filtration rate (e GFR).
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk is increased with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft (CABG) surgery.
Increased risk of cardiovascular thrombotic events; risk of serious GI adverse events including bleeding, ulceration, and perforation; renal toxicity; hypertension; anaphylactoid reactions; serious skin reactions; hematologic toxicity; avoid in advanced renal disease.
Cardiovascular risk: May increase risk of serious cardiovascular thrombotic events.,Gastrointestinal risk: Can cause serious GI adverse events including bleeding, ulceration, and perforation.,Renal toxicity: Monitor renal function; avoid in patients with advanced renal disease.,Hepatic effects: Elevations in liver enzymes; discontinue if signs of hepatic injury occur.,Anaphylactoid reactions: Can occur in patients without prior exposure.,Pregnancy: Avoid in late pregnancy due to risk of premature closure of ductus arteriosus.
Hypersensitivity to ibuprofen or other NSAIDs; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; active GI bleeding; history of recurrent peptic ulcer disease; severe heart failure.
Hypersensitivity to ketorolac or any NSAID,Active peptic ulcer disease or GI bleeding,Advanced renal impairment (creatinine clearance <30 m L/min),Patients at risk for bleeding or receiving anticoagulants,Labor and delivery (risk of fetal harm),Treatment of perioperative pain in CABG surgery,Concomitant use with other NSAIDs or aspirin,Intrathecal or epidural administration (contains alcohol)
Concurrent alcohol consumption increases risk of GI bleeding and ulceration. Avoid high-sodium foods to minimize fluid retention and potential exacerbation of hypertension. Grapefruit juice may slightly reduce rate of absorption but is not clinically significant.
No specific food interactions. Avoid alcohol as it may increase risk of GI bleeding. Take with food or milk to minimize GI upset.
Motrin (ibuprofen) is an NSAID. First trimester: Risk of miscarriage and congenital malformations, particularly cardiac defects, with use. Second trimester: Generally considered safer but avoid prolonged use due to potential for oligohydramnios. Third trimester: Contraindicated after 20 weeks due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal complications including pulmonary hypertension and renal impairment.
Pregnancy Category C. Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. No adequate studies in first two trimesters; use only if potential benefit justifies risk.
Ibuprofen is excreted into breast milk in very small amounts. The M/P ratio is approximately 0.01. The relative infant dose is less than 1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but avoid high doses or prolonged use.
Excreted in human milk in low amounts. M/P ratio not available. Consider risk of infant NSAID exposure; use with caution, especially in neonates.
No dose adjustment is recommended in pregnancy; however, use should be restricted to the lowest effective dose for the shortest duration possible. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce plasma concentrations, but no formal dose adjustment studies exist. Avoid use after 20 weeks gestation.
No specific dose adjustments recommended for pharmacokinetic changes in pregnancy. Use lowest effective dose for shortest duration.
For acute pain, use lowest effective dose for shortest duration to minimize GI and renal risks. Administer with food or milk to reduce GI irritation. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) or active peptic ulcer disease. Ibuprofen can mask fever, making infection detection difficult. Caution in asthma patients as it may precipitate bronchospasm. Monitor blood pressure in hypertensive patients due to potential for fluid retention.
SPRIX (ketorolac tromethamine) is an NSAID nasal spray for acute pain. Use lowest effective dose for shortest duration. Avoid in patients with active peptic ulcer, recent GI bleeding, renal impairment (Cr Cl <30 m L/min), or at risk of bleeding. Contraindicated in patients with aspirin or NSAID allergy, and in patients with or at risk of intracranial bleeding. Monitor renal function and GI symptoms. Not for use in pediatric patients. Maximum duration is 5 days.
Take with food or milk to prevent stomach upset.,Do not exceed 1200 mg per day for OTC use (adults) or as directed by your doctor.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Stop use and consult doctor if symptoms persist for more than 10 days (pain) or 3 days (fever).,Do not take with other NSAIDs or pain relievers without consulting your healthcare provider.,Notify your doctor if you have a history of heart disease, high blood pressure, or stomach ulcers.
Use exactly as prescribed; do not exceed 5 days of therapy.,Spray into nostril; do not sniff deeply after spraying.,Avoid alcohol and other NSAIDs while using this medication.,Seek medical help if you experience signs of bleeding, stomach pain, or allergic reaction.,Store at room temperature; do not refrigerate or freeze.,Tell your doctor about all other medications you take, especially blood thinners or other NSAIDs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOTRIN vs SPRIX, answered by our medical review team.
MOTRIN is a NSAID Analgesic that works by Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis.. SPRIX is a NSAID Analgesic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOTRIN and SPRIX depend on the specific clinical indication. These are both NSAID Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOTRIN is: Ibuprofen (Motrin) 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day for acute pain, and 2400 mg/day for chronic use.. The standard adult dose of SPRIX is: Intranasal: 31.5 mg (1 spray) in one nostril, may repeat after 30 minutes; maximum 63 mg (2 sprays) per dose. Subsequent doses every 6-8 hours as needed; maximum 126 mg (4 sprays) per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOTRIN and SPRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOTRIN is classified as Category C. Motrin (ibuprofen) is an NSAID. First trimester: Risk of miscarriage and congenital malformations, particularly cardiac defects, with use. Second trimester: Generally considered sa. SPRIX is classified as Category C. Pregnancy Category C. Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. No adequate studies in first two trimesters; use only if p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.